MedDataX Logo

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

NCT ID: NCT01399619

Last Updated: 2016-08-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

310 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 24-48 weeks, according to re-randomisation of Early Treatment Success (ETS) patients at 24 weeks to stop PegIFN/RBV or continue PegIFN/RBV until week 48. If no ETS, then PegIFN/RB for 48 weeks, in HCV treatment-naive or relapsers patients coinfected with HIV

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864

Hepatitis C, Chronic
COMPLETED PHASE3

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

NCT01343888

Hepatitis C
COMPLETED PHASE3

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270

Hepatitis C
COMPLETED PHASE3

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793

Hepatitis C, Chronic
COMPLETED PHASE1

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

NCT01608737

Hepatitis C, Chronic
WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI201335 12W

patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks

Group Type EXPERIMENTAL

PegIFN/RBV

Intervention Type DRUG

PegIFN/RBV for 24 or 48w

BI201335

Intervention Type DRUG

BI201335 for 12w

BI 201335 24W

patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks

Group Type EXPERIMENTAL

BI201335 24W

Intervention Type DRUG

BI201335 for 24w

PegIFN/RBV

Intervention Type DRUG

PegIFN/RBV for 24 or 48w

BI 201335 24 W

patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks

Group Type EXPERIMENTAL

PegIFN/RBV

Intervention Type DRUG

PegIFN/RBV for 24 or 48w

Bi 201335

Intervention Type DRUG

BI 201335 for 24 w

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PegIFN/RBV

PegIFN/RBV for 24 or 48w

Intervention Type DRUG

PegIFN/RBV

PegIFN/RBV for 24 or 48w

Intervention Type DRUG

BI201335

BI201335 for 12w

Intervention Type DRUG

BI201335 24W

BI201335 for 24w

Intervention Type DRUG

PegIFN/RBV

PegIFN/RBV for 24 or 48w

Intervention Type DRUG

Bi 201335

BI 201335 for 24 w

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Chronic hepatitis C (HCV) genotype 1 infection
2. Chronic Human Immunodeficiency Virus (HIV) -1 infection
3. HCV treatment naive or HCV treatment experienced but only relapsers
4. Age 18 to 70 years
5. Antiretroviral treatment naive or on stable Highly Active Antiretroviral Therapy (HAART)
6. Karnofsky score \>70
7. HCV viral load \>1.000 IU/mL

Exclusion Criteria

1. HCV infection of mixed genotype (1/2, 1/3, 1/4)
2. Evidence of acute or chronic liver due to chronic HCV infection
3. Hepatitis B virus (HBV) infection with presence of HBs-Ag
4. Active malignancy or history or malignancy within the last 5 years
5. Received concomitant systemic antiviral (other than antiretroviral), hematopoietic growth factor or immunomodulatory treatment in 28 days prior enrolment.
6. Decompensated liver disease,as evidenced by ascites, hepatic encephalopathy, esophageal variceal bleeding, and/or laboratory values that add up to \>/= 7 points according tho the Child-Turcotte-Pugh classification
7. Hemoglobin \</=11g/dL for women and \</= 12 g/dL for men
8. Patients with stable cardiac disease and Hemoglobin \<12g/dL
9. Known hypersensitivity to any ingredient of the study drugs
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1220.19.0045 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

1220.19.0007 Boehringer Ingelheim Investigational Site

Palm Springs, California, United States

Site Status

1220.19.0031 Boehringer Ingelheim Investigational Site

San Francisco, California, United States

Site Status

1220.19.0005 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

Site Status

1220.19.0086 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

1220.19.0044 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

1220.19.0004 Boehringer Ingelheim Investigational Site

Vero Beach, Florida, United States

Site Status

1220.19.0079 Boehringer Ingelheim Investigational Site

Lutherville, Maryland, United States

Site Status

1220.19.0027 Boehringer Ingelheim Investigational Site

Framingham, Massachusetts, United States

Site Status

1220.19.0008 Boehringer Ingelheim Investigational Site

Camden, New Jersey, United States

Site Status

1220.19.0009 Boehringer Ingelheim Investigational Site

Hillsborough, New Jersey, United States

Site Status

1220.19.0011 Boehringer Ingelheim Investigational Site

Albany, New York, United States

Site Status

1220.19.0006 Boehringer Ingelheim Investigational Site

New York, New York, United States

Site Status

1220.19.0014 Boehringer Ingelheim Investigational Site

New York, New York, United States

Site Status

1220.19.0084 Boehringer Ingelheim Investigational Site

New York, New York, United States

Site Status

1220.19.0021 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

1220.19.0013 Boehringer Ingelheim Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

1220.19.0029 Boehringer Ingelheim Investigational Site

Austin, Texas, United States

Site Status

1220.19.0012 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1220.19.0060 Boehringer Ingelheim Investigational Site

Fort Worth, Texas, United States

Site Status

1220.19.0016 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

1220.19.0026 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Site Status

1220.19.5508 Boehringer Ingelheim Investigational Site

Rio de Janeiro, , Brazil

Site Status

1220.19.5502 Boehringer Ingelheim Investigational Site

Rio de Janeiro - RJ, , Brazil

Site Status

1220.19.5506 Boehringer Ingelheim Investigational Site

Salvador, , Brazil

Site Status

1220.19.5503 Boehringer Ingelheim Investigational Site

São Paulo, , Brazil

Site Status

1220.19.5505 Boehringer Ingelheim Investigational Site

São Paulo, , Brazil

Site Status

1220.19.5501 Boehringer Ingelheim Investigational Site

São Paulo - SP, , Brazil

Site Status

1220.19.3306 Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

1220.19.3303 Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

1220.19.3304 Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

1220.19.3301 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1220.19.3305 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1220.19.3307 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1220.19.4902 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1220.19.4921 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1220.19.4901 Boehringer Ingelheim Investigational Site

Bonn, , Germany

Site Status

1220.19.4924 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

1220.19.4919 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1220.19.4920 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1220.19.4905 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

1220.19.4922 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

1220.19.4923 Boehringer Ingelheim Investigational Site

Würzburg, , Germany

Site Status

1220.19.3901 Boehringer Ingelheim Investigational Site

Antella (fi), , Italy

Site Status

1220.19.3902 Boehringer Ingelheim Investigational Site

Bari, , Italy

Site Status

1220.19.3906 Boehringer Ingelheim Investigational Site

Brescia, , Italy

Site Status

1220.19.3907 Boehringer Ingelheim Investigational Site

Milan, , Italy

Site Status

1220.19.3905 Boehringer Ingelheim Investigational Site

Pavia, , Italy

Site Status

1220.19.3903 Boehringer Ingelheim Investigational Site

Roma, , Italy

Site Status

1220.19.3904 Boehringer Ingelheim Investigational Site

Torino, , Italy

Site Status

1220.19.3404 Boehringer Ingelheim Investigational Site

Badalona, , Spain

Site Status

1220.19.3401 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1220.19.3403 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1220.19.3409 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1220.19.3402 Boehringer Ingelheim Investigational Site

L'Hospitalet de Llobregat, , Spain

Site Status

1220.19.3405 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1220.19.3406 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1220.19.3407 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1220.19.3408 Boehringer Ingelheim Investigational Site

Seville, , Spain

Site Status

1220.19.4101 Boehringer Ingelheim Investigational Site

Basel, , Switzerland

Site Status

1220.19.4103 Boehringer Ingelheim Investigational Site

Bern, , Switzerland

Site Status

1220.19.4102 Boehringer Ingelheim Investigational Site

Lugano, , Switzerland

Site Status

1220.19.4104 Boehringer Ingelheim Investigational Site

Zurich, , Switzerland

Site Status

1220.19.4406 Boehringer Ingelheim Investigational Site

Brighton, , United Kingdom

Site Status

1220.19.4407 Boehringer Ingelheim Investigational Site

Edinburgh, , United Kingdom

Site Status

1220.19.4401 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1220.19.4402 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1220.19.4403 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1220.19.4404 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1220.19.4408 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1220.19.4405 Boehringer Ingelheim Investigational Site

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Brazil France Germany Italy Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Dieterich D, Nelson M, Soriano V, Arasteh K, Guardiola JM, Rockstroh JK, Bhagani S, Laguno M, Tural C, Ingiliz P, Jain MK, Stern JO, Manero M, Vinisko R, Kort J; STARTVerso4 study group. Faldaprevir and pegylated interferon alpha-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. AIDS. 2015 Mar 13;29(5):571-81. doi: 10.1097/QAD.0000000000000579.

Reference Type DERIVED
PMID: 25710287 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-021734-59

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1220.19

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
NCT01330316 COMPLETED PHASE3
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
NCT01858961 WITHDRAWN PHASE3
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
NCT01732796 COMPLETED PHASE3
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
NCT01728324 COMPLETED PHASE3
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
NCT00774397 COMPLETED PHASE2
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
NCT01132313 COMPLETED PHASE2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
NCT00947349 COMPLETED PHASE2
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
NCT01859962 COMPLETED PHASE2
BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3
NCT01830127 COMPLETED PHASE2
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
NCT00332176 UNKNOWN PHASE2
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
NCT01903954 COMPLETED PHASE2
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
NCT00217139 COMPLETED PHASE2
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
NCT01591460 COMPLETED PHASE4
Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
NCT01579474 COMPLETED PHASE3
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
NCT01508130 COMPLETED
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
NCT01573351 COMPLETED PHASE3
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
NCT01525628 COMPLETED PHASE1
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
NCT00395421 COMPLETED PHASE2
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
NCT00758043 COMPLETED PHASE3
Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
NCT01335529 COMPLETED PHASE2
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
NCT02593162 COMPLETED PHASE2
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
NCT00735969 COMPLETED PHASE2
Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)
NCT00984620 COMPLETED PHASE2
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
NCT00959699 COMPLETED PHASE2
4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
NCT00905632 COMPLETED PHASE1